gemcitabine

Subscribe to Selected New Research on gemcitabine

3706 relevant articles (547 outcomes, 1700 trials/studies) found for this Drug

Description: structure given in first source; RN given refers to (D-erythro)-isomer

Also Known As:

2',2'-DFDC; 2',2'-difluoro-2'-deoxycytidine; 2',2'-difluorodeoxycytidine; 2'-deoxy-2',2''-difluorocytidine-5'-O-monophosphate; 2'-deoxy-2'-difluorocytidine; Gemzar; LY 188011; LY-188011; dFdCyd; gemcitabine, (D-threo-pentafuranosyl)-isomer; gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer; gemcitabine, (beta-D-threo-pentafuranosyl)-isomer

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

Pyrimidines: 269

Pyrimidine Nucleosides: 38

Cytidine: 276

Deoxycytidine: 791

gemcitabine: 3706

Nucleic Acids, Nucleotides, and Nucleosides: 1

Nucleosides: 591

Pyrimidine Nucleosides: 38

Cytidine: 276

Deoxycytidine: 791

gemcitabine: 3706

Deoxyribonucleosides: 28

Deoxycytidine: 791

gemcitabine: 3706

Experts

1.	Georgoulias, V: 21 articles (05/2008 - 02/2000)
2.	Heinemann, Volker: 16 articles (05/2008 - 02/2002)
3.	Zalupski, Mark M: 13 articles (02/2008 - 05/2002)
4.	Peters, G J: 13 articles (10/2006 - 10/2000)
5.	Gridelli, Cesare: 12 articles (07/2008 - 01/2003)
6.	Lorusso, V: 12 articles (06/2008 - 01/2000)
7.	Georgoulias, Vassilis: 12 articles (05/2008 - 05/2002)
8.	Conte, P F: 12 articles (05/2006 - 02/2000)
9.	Mavroudis, D: 11 articles (05/2008 - 02/2000)
10.	Comella, P: 11 articles (02/2007 - 02/2000)

Related Diseases

1.	Pancreatic Neoplasms (Pancreatic Cancer) 04/15/2007 - "Gemcitabine is currently the best treatment available for pancreatic cancer, but the disease develops resistance to the drug over time" 09/01/2001 - "Gemcitabine is currently the most effective chemotherapeutic drug available for patients with pancreatic cancer, but is only minimally effective against this aggressive disease" 02/20/2008 - "PURPOSE: Gemcitabine is effective in the treatment of pancreatic cancer and is a potent radiosensitizer" 01/01/2007 - "CONCLUSION: This meta-analysis of data obtained from randomised controlled phase II-III trials of patients with advanced pancreatic cancer showed a small but significant improvement in overall survival for patients receiving gemcitabine-based doublets compared with gemcitabine alone." 05/01/2008 - "RESULTS: There was a significant reduction in proliferation in the pancreatic cancer cell lines treated with a combination of gemcitabine and LDM" Get all the results and reference details, order at left...
2.	Neoplasms (Cancer) 11/01/2008 - "CONCLUSION: Gemcitabine fulfills all requirements as an alternative agent in treating BCG failure patients with low adverse events, well tolerated, and highly effective in reducing tumor recurrences." 08/01/2006 - "The significantly improved therapeutic outcome of animals receiving the triple therapy was attributed to multiple factors, including most likely improved FMG expression throughout the tumor and enhanced sensitivity of the tumor cells to gemcitabine by adenoviral gene products but also FMG expression" 07/01/2003 - "Gemcitabine highly improved survival (72 days, P = 0.004) by inducing transient tumor regression over the first 3 weeks" 01/01/2008 - "The liposomal formulations considerably increased the half-life and the area under the curve (AUC) of gemcitabine, and simultaneously caused a marked improvement in the anticancer activity against experimental solid tumors developed orthotopically or at subcutaneous site" 08/01/2007 - "Furthermore, gemcitabine treatment together with either AdhHM plus agonistic anti-GITR antibody administration or alphaGalCer-loaded DC transduced with AdhHM showed potent therapeutic antitumor immunity and perfect protection against preexisting tumors" Get all the results and reference details, order at left...
3.	Small Cell Carcinoma (Small Cell Lung Cancer) 12/05/2005 - "Although gemcitabine is a potent therapeutic agent in the treatment of human non-small cell lung cancer (NSCLC), resistance to gemcitabine is common" 05/01/1996 - "As the efficacy of gemcitabine in non-small cell lung cancer was equivalent when using both regimens, the better tolerated and more easily administered once-weekly schedule is recommended." 09/01/2004 - "We have found that single-agent gemcitabine represent a sufficiently safe therapeutic option in unfit patients with inoperable non-small cell carcinoma (NSCLC)." 12/01/2002 - "Weekly administration of gemcitabine in an outpatient setting is a useful treatment for inoperable or recurrent non-small cell lung cancer." 12/01/2007 - "This study was to investigate the efficacy of gemcitabine with concurrent radiotherapy on stage III, inoperable non-small cell lung cancer (NSCLC), and observe the adverse events and long-term survival of the patients" Get all the results and reference details, order at left...
4.	Breast Neoplasms (Breast Cancer) 04/01/2003 - "Data from phase II clinical studies suggest that gemcitabine/anthracycline combinations are relatively effective in first- or second-line therapy for women with locally advanced and metastatic breast cancer" 04/01/2005 - "CONCLUSION: Gemcitabine monotherapy is effective and safe as salvage treatment in heavily pretreated, breast cancer patients." 08/20/2008 - "CONCLUSION: This phase III study documents a role for gemcitabine in advanced breast cancer after anthracycline-based adjuvant therapy" 04/22/2008 - "This study examined the pathological complete response (pCR) rate and safety of sequential gemcitabine-based combinations in breast cancer" 10/01/2007 - "Study supports activity of gemcitabine in treatment of early-stage breast cancer." Get all the results and reference details, order at left...
5.	Carcinoma (Carcinomatosis) 09/01/2007 - "Here, a murine pancreatic carcinoma model was used to investigate whether combination with gemcitabine increases therapeutic efficacy of DC-based vaccination" 06/15/2003 - "BACKGROUND: The objectives of the current study were to determine the maximum tolerated dose and to evaluate the efficacy of gemcitabine given in combination with strontium-89 to patients with androgen independent prostate carcinoma" 10/01/2006 - "CONCLUSIONS: At the dose regimens employed, gemcitabine did not enhance the efficacy of RIT of experimental small-volume peritoneal carcinomatosis of colonic origin." 04/01/2006 - "The role of gemcitabine in first-line treatment of advanced ovarian carcinoma." 09/15/2005 - "Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree." Get all the results and reference details, order at left...
292 Diseases and 3706 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Cisplatin (Platino)
2.	Paclitaxel (Taxol)
3.	docetaxel (Taxotere)
4.	vinorelbine (Navelbine)
5.	Carboplatin (JM8)
6.	gemcitabine
7.	Fluorouracil (Carac)
8.	Platinum
9.	oxaliplatin (Eloxatin)
10.	irinotecan (Camptosar)
685 Drugs and Important Bio-Agents and 2758 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Combination Drug Therapy (Combination Chemotherapy)
3.	Heterologous Transplantation (Xenotransplantation)
4.	Adjuvant Chemotherapy
5.	Palliative Care (Palliative Medicine)
46 Therapies and Procedures and 1115 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>